Corticosteroids in Myositis and Scleroderma.

Area of Science:

• Rheumatology and Immunology
• Neuromuscular Disorders

Background:

• Idiopathic inflammatory myopathies (IIMs) are a group of rare autoimmune diseases characterized by muscle inflammation.
• IIMs encompass dermatomyositis, polymyositis, inclusion body myositis, and immune-mediated necrotizing myopathy, distinguished by clinical and histopathological features.
• Systemic corticosteroids (CS) are the cornerstone of IIM treatment, particularly when muscle and organ involvement is present.

Purpose of the Study:

• To review the role of corticosteroids in managing idiopathic inflammatory myopathies.
• To highlight the risks associated with high-dose CS, such as scleroderma renal crisis in systemic sclerosis.
• To emphasize the need for adjunctive immunosuppressive therapies to mitigate CS side effects and facilitate dose reduction.

Main Methods:

• Literature review of current treatment guidelines and clinical trial data for IIMs.
• Analysis of the efficacy and safety profiles of systemic corticosteroids in IIM management.
• Examination of evidence supporting the use of concomitant immunosuppressive agents in IIM therapy.

Main Results:

• Systemic corticosteroids are effective first-line treatments for IIMs with significant muscle and organ involvement.
• High-dose CS therapy carries risks, including potential for serious adverse events like scleroderma renal crisis in susceptible patients.
• Concomitant immunosuppressive medications can enable effective CS tapering and reduce the overall side effect burden.

Conclusions:

• While CS are crucial for IIM treatment, their use should be carefully monitored due to potential adverse effects.
• Integrating other immunosuppressants alongside CS is a key strategy for optimizing IIM management and improving patient outcomes.
• Further research may explore optimal combinations and sequencing of therapies to maximize efficacy and minimize toxicity in IIM patients.